PHASE-II TRIAL OF RECOMBINANT INTERFERON-ALPHA WITH BCNU, CISPLATIN, DTIC AND TAMOXIFEN IN ADVANCED MALIGNANT-MELANOMA

被引：14

作者：

FEUN, LG

SAVARAJ, N

MOFFAT, F

ROBINSON, D

LIEBMANN, A

HURLEY, J

RAUB, WA

RICHMAN, SP

机构：

[1] Sylvester Comprehensive Cancer Center, Division of Medical Oncology/Hematology, Department of Medicine University of Miami, Miami, FL, 33136

来源：

MELANOMA RESEARCH | 1995年 / 5卷 / 04期

关键词：

INTERFERON; MELANOMA;

D O I：

10.1097/00008390-199508000-00011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-alpha (IFN-alpha) have each produced responses in advanced malignant melanoma, a phase II trial was conducted to evaluate the response and toxicity of simultaneous administration of both therapies. Of 33 assessable patients, two (6%) had complete response (CR) and 12 patients (36%) had partial response (PR), for a total response rate (CR + PR) of 42% (95% confidence interval 26-58). Four patients had minor response (12%). Mixed responses occurred in five patients (15%). The remaining patients had progressive disease. The duration of CR was 3, 7 and 17 (+) months and the duration of PR was 3+ to 19+ months (median 6 months). The median overall survival for all patients entered into the study was 5 months. Main toxicities included myelosuppression and fatigue. Combined simultaneous cytotoxic chemotherapy and IFN produced a high response rate (42%) which is comparable to that reported for chemotherapy alone. Further studies are needed to determine the optimal schedule for combining chemotherapy and immunotherapeutic agents as well as the impact of biological agents on survival in the treatment of melanoma.

引用

页码：273 / 276

页数：4

共 17 条

[1]

McClay F.F., Mastrangelo M.J., Systemic chemotherapy for metastatic melanoma in Sem, Oncology, 15, pp. 569-577, (1998)

[2]

Legha S., Interferon in the treatment of malignant melanoma, Biother Cancer, 1, pp. 1-5, (1988)

[3]

Wadler S., Schwartz E., Interferon as modulator of cytotoxic drugs, Medguide Oncol, (1990)

[4]

Kaplan E.L., Meier P., Non parametric estimation from incomplete observations, J am Stat Assoc, 53, pp. 457-481, (1953)

[5]

Namba M., Yamaolo S., Tanaka H., Et al., In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells, Cancer, 54, pp. 2262-2267, (1984)

[6]

Carmicheal J., Ferguson R.J., Wolf C.R., Et al., Augmentation of cytotoxicity of chemotherapy by human alpha interferon in humun non-small cell lung cancer xenografts, Cancer Res, 46, pp. 1916-1920, (1986)

[7]

Vorobiol D.A., Falkson G., Voges C.W., DTIC Versus DTIC and recombinant interferon alfa 26 GIFN α 260 in the treatement of the patients (Pts) with advanced malidnant melanoma (mm), Proc Am Soc Clin Oncol, 8, (1989)

[8]

Falkson C.I., Falkson H., Falkson H.C., Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma, J Clin Oncol, 9, pp. 1403-1408, (1991)

[9]

Smith J., Ferguson R., Stewart M., Et al., Alpha interferon potentiates cisplatin in patients with non-small cell lung cancer, Proc Am Soc Clinic Oncol, 7, (1988)

[10]

Saito T., Verens M.E., Welarden C.E., Interferon and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay, Cancer Chemother Pharmacol, 19, pp. 233-239, (1987)

← 1 2 →